CAS: 38953-42-3; 4-Amino-6-Chloropyrimidin-5-Ol

相似化合物

5018-41-7 943995-31-1 2890217-51-1

上下游产品

6-chloro-5-methoxypyrimidine-4-amine

6-Chloro-5-Methoxy-N-[(4-Methoxyphenyl)Methyl]-4-Pyrimidinamine置于三溴化硼体系中,用 二氯甲烷 作为反应溶剂,化学反应生成 4-氨基-6-氯-5-羟基嘧啶
参考文献:一种fgfr4激酶抑制剂及其制备方法和用途
标题:一种fgfr4激酶抑制剂及其制备方法和用途
摘要:本发明涉及式(I)化合物,或其药学上可接受的盐,溶剂化物,多晶型物或异构体,及其在制备用来治疗fgfr4介导的疾病的药物中的用途.

专利信息

专利号:US-10112955-B2
优先权日:2015-10-29
标题 :Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
发明人：SPRENGELER PAUL A; REICH SIEGFRIED H; ERNST JUSTIN T; WEBBER STEPHEN E; SHAGHAFI MIKE; MURPHY DOUGLAS; TRAN CHINH
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , W 1 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7 , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b , and R 10 and subscript “nâ€? are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.